Back to Results
First PageMeta Content
Medicine / Galeterone / Prostate cancer


NEWS RELEASE FOR IMMEDIATE RELEASE Tokai Pharmaceuticals Appoints John McBride as Chief Operating Officer CAMBRIDGE, Mass., February 11, 2014 – Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on devel
Add to Reading List

Document Date: 2014-02-11 08:59:12


Open Document

File Size: 121,35 KB

Share Result on Facebook

Company

Gloucester Pharmaceuticals Inc. / Apple Tree Partners / Pharmacia Corporation / Sparta Pharmaceuticals Inc. / Tokai Pharmaceuticals Inc. / CytoTherapeutics Inc. / Tokai Pharmaceuticals Tokai Pharmaceuticals / Alliance Life Science Advisors Inc. / U.S. Bioscience Inc. / Phytera Inc. / /

Event

Employment Change / FDA Phase / Funding / /

Facility

University of Pennsylvania / University of Wisconsin / /

IndustryTerm

pharmaceutical experience / biopharmaceutical / chemical engineering / treatment of castration-resistant prostate cancer / finance / manufacturing functions / /

MedicalCondition

cancers / castration-resistant prostate cancer / seizures / castrationresistant prostate cancer / prostate cancer / /

Organization

Novartis Venture Fund / Wharton School / University of Pennsylvania / University of Wisconsin / Satter Foundation / /

Person

John McBride / Jodie Morrison / /

Position

executive vice president and chief operating officer / executive vice president / business operations and chief financial officer / driver / Chief Operating Officer / vice president / commercial development / president / president and chief executive officer / global head of oncology licensing / vice president / business development / candidate galeterone / vice president / business development and treasurer / /

Product

prednisone / ARMOR2 / /

ProvinceOrState

Wisconsin / Pennsylvania / Massachusetts / /

URL

www.tokaipharma.com / /

SocialTag